Strides Pharma Science Ltd Corporate Actions

Strides Pharma Q3 Profit at ₹90 Crore, Revenue Up 15%

 Copy Link

EBITDA grew 48% YoY at ₹210 crore, from ₹142 crore in the same quarter last year, marking better profitability.

Strides Pharma Posts ₹93 Crore Q2 Profit

 Copy Link

EBITDA rose significantly to ₹235.7 Crore, a 54% increase from ₹153 Crore in the corresponding period of the previous year.

Strides Pharma gets shareholders’ approval for CDMO unit

 Copy Link

In September 2023, the pharmaceutical behemoth revealed OneSource. The stock exchanges approved the idea earlier this year, in May.

Strides gets US FDA nod for Theophylline tablets

 Copy Link

The medication is bioequivalent and therapeutically equivalent to Schering Corp's Reference Listed Drug (RLD), THEO-DUR.

Strides Pharma's Chennai Facility Receives USFDA Approval

 Copy Link

The Alathur facility is key to Strides' global operations, especially in the US and other regulated markets, specializing in the production of tablets and capsules.